Lishengpharma: Potassium Chloride Sustained-Release Tablets have passed the market approval application
I'm PortAI, I can summarize articles.
Lishengpharma announced that the company has obtained the drug registration certificates for potassium chloride sustained-release tablets in specifications of 0.5g and 0.6g issued by the National Medical Products Administration, marking the approval of the drug for market licensing application. This drug is suitable for the treatment and prevention of hypokalemia, especially in cases where dietary management or reduced diuretic treatment is ineffective
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments